Skip to main content

Table 1 Characteristics of the centers that participated in the survey

From: Onabotulinumtoxin A for the management of chronic migraine in current clinical practice: results of a survey of sixty-three Italian headache centers

Answer options n (%)
Number of patients treated on a monthly basis with Onabotulinumtoxin A (OBT-A)
 < 5 patients 15 (23.8)
 5−10 patients 21 (33.3)
 10−20 patients 18 (28.6)
 20−40 patients 5 (7.9)
 > 40 patients 4 (6.4)
Years of experience with OBT-A for chronic migraine
 > 1 year and ≤3 years 39 (61.9)
 > 3 years 24 (38.1)
Longest follow-up of patients treated with OBT-A for chronic migraine
 1 year 13 (20.6)
 2 years 24 (38.1)
 3 years 18 (28.6)
 ≥ 4 years 8 (12.7)
Availability of electronic data recording system
 Yes 45 (71.4)
 No 18 (28.6)
Availability of a facility dedicated to the treatment of chronic migraine with OBT-A
 Yes 51 (81.9)
 No 12 (19.1)